Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zacks Investment Research on MSN
MDGL stock down despite Q2 beat, MASH drug drives top-line Y/Y growth
Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus ...
“The question early on was what mechanisms we wanted,” Madrigal CEO Bill Sibold told Fierce in an interview at the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results